Apimeds Pharmaceuticals US, Inc. (APUS) stock
APUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 2/30
$1.89−0.06 (-3.08%)
Close on Nov 18, 2026Market cap $2.85MP/E –Yield –
Apimeds Pharmaceuticals US operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Apimeds Pharmaceuticals US's operating income for the twelve months ending Sep 30, 2026 was -$23.47M. For fiscal 2025 it was -$11.91M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.91M | – |
| FY2024 | Dec 31, 2024 | -$1.28M | – |
| FY2023 | Dec 31, 2023 | -$747.44K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.03M | – |
| Q2 FY2026 | Jun 30, 2026 | -$6.28M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.19M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.04M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.84M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.66M | – |
| Q1 FY2025 | Mar 31, 2025 | -$364.37K | – |
| Q4 FY2024 | Dec 31, 2024 | -$275.61K | – |
| Q3 FY2024 | Sep 30, 2024 | -$300.00K | – |
| Q2 FY2024 | Jun 30, 2024 | -$427.76K | – |
| Q1 FY2024 | Mar 31, 2024 | -$271.73K | – |
See a number that looks wrong?